Mammalian telomerase

Details Mammalian telomerase Mammalian telomerase

2003-02-07

2010-06-08

Angell, J. E (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C435S006120

Reexamination Certificate

active

07732402

ABSTRACT:
Nucleic acids comprising the RNA component of a mammalian telomerase are useful as pharmaceutical, therapeutic, and diagnostic reagents.

REFERENCES:
patent: 4737454 (1988-04-01), Dattagupta et al.
patent: 5270201 (1993-12-01), Richards et al.
patent: 5489508 (1996-02-01), West et al.
patent: 5496698 (1996-03-01), Draper et al.
patent: 5583016 (1996-12-01), Villeponteau et al.
patent: 5643890 (1997-07-01), Iversen et al.
patent: 5645986 (1997-07-01), West et al.
patent: 5958680 (1999-09-01), Villeponteau et al.
patent: 6548298 (2003-04-01), Villeponteau et al.
patent: 0 666 313 (1995-08-01), None
patent: 10-234384 (1998-09-01), None
patent: 9002757 (1990-03-01), None
patent: WO-92/02228 (1992-02-01), None
patent: WO-93/23572 (1993-11-01), None
patent: WO-95/13382 (1995-05-01), None
patent: WO-96/01614 (1996-01-01), None
patent: WO-96/01835 (1996-01-01), None
patent: WO-98/07838 (1998-02-01), None
Scherer et al. (Nat. Biotechnol., 2003, 21(12), pp. 1457-1465).
Jen et al. (Stem Cells, 2000, vol. 18, p. 307-319).
Opalinska et al. (Nature Reviews Drug Discovery, 2002, vol. 1, p. 503-514).
Braasch et al. (Biochemistry 2002, vol. 41(14), pp. 4503-4510).
Branch et al. (Trends Biochem Sci, 1998, vol. 23(2), pp. 45-50).
Blackburn (1991), “Structure and function of telomeres,”Nature350:569-573.
Blackburn (1992), “Telomerases,”Ann. Rev. Biochem.61:113-129.
Blackburn et al. (Jan. 1989), “Recognition and elongation of telomeres by telomerase,”Genome31:553-560.
Counter et al. (1992), “Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity,”EMBO J.11(5):1921-1929.
Czech (Nov. 25, 1988), “Ribozymes and their medical implications,”JAMA260 (20):3030-3034.
Eck and Nabel (1991), “Antisense oligonucleotides for therapeutic intervention,”Current Opinions Biotechnology2:897-904.
Greider (Sep. 1991), “Telomerase is processive,”Mol. Cell. Bio.11:4572-4580.
Greider and Blackburn (Dec. 24, 1987), “The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity,”Cell51:887-898.
Greider and Blackburn (Jan. 26, 1989), “A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis,”Nature337 (6205):331-337.
Harley et al. (May 31, 1990), “Telomeres shorten during ageing of human fibroblasts,”Nature345:458-460.
Harley et al. (1991), “Telomere loss: Mitotic clock or genetic time bomb?”Mut. Res.256:271-282.
Morin (Nov. 3, 1989), “The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG Repeats,”Cell, 59:521-529.
Morin (Oct. 8, 1991), “Recognition of a chromosome truncation site associated with alpha-thalassaemia by human telomerase,”Nature353:454-456.
Romero and Blackburn (Oct. 18, 1991), “A conserved secondary structure for telomerase RNA,”Cell67:343-353.
Shippen-Lentz and Blackburn (Feb. 2, 1990), “Functional evidence for an RNA template in telomerase,”Science247:546-552.
Yu et al. (Mar. 8, 1990), “In vitro alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs,”Nature344:126-132.
Yu and Blackburn (Nov. 15, 1991), “Developmentally programmed healing of chromosomes by telomerase in Tetrahymena,”Cell67:823-832.
Zahler et al. (Apr. 25, 1991), “Inhibition of telomerase by G-quartet DNA structures,”Nature350:718-720.
Lingner et al. (1984), “Telomerase RNAs of different ciliates have a common secondary structure and a permuted template,”Genes and Development8:1989-1998.
Singer and Gottschling (1994), “TLC1: Template RNA Component ofSaccharomyces cerevisiaeTelomerase,”Science266:404-409.
Kim et al. (1994), “Specific Association of Human Telomerase Activity with Immortal Cells and Cancer,”Science266:2011-2014.
Blackburn, E.H., “Telomeres,”TIBS, 16:378-381 (1991).
Blackburn, E.H., Grant Abstracts 5R01 GM 32565-11; 5P30 ES01896-15UB; 5R37 GM26259-16.
Counter et al., “Telomerase activity in human overian carcinoma,”PNAS, 91:2900-2904 (1994).
Feng, J. et al., “The RNA Component of Human Telomerase,”Science, 269 1236-1241 (1995).
Grieder, C.W., “Telomerase and Telomere-length Regulation: Lessons from Small Eukaryotes to Mammals,”Cold Spring Harbor Symposia on Quantitative Biology, vol. LVIII, Cold Spring Harbor Laboratory, New York (1993).
Grieder, C.W., Grant Abstracts 5R01 RG09383-03; 5R01 GM43080-04.
Nilsson, P. et al., “Telomerase activity in vivo in human malignant hematopoietic cells,”Oncogene, 9:3043-3048 (1994).
Prowse, et al., “Identification of a nonprocessive telomerase activity from mouse cells,”Proc. Nat. Acad. Sci. USA, 90:1493-1497 (1993).
Rennie, J., “Immortal's Enzyme,”Scientific American, Jul. 1994, pp. 14-16 (1994).
Rensberger, B. “Cancer's Immortality May Depend on Enzyme,”Washington Post, Apr. 12, 1994, p. A1, A12.
Yan et al., “Amino Acid Sequence of the Human Protein Synthesis Initiation Factor eIF-4γ,”J. Biol. Chem., 267:23226-23231 (1992).
Pestka et al., “Antisense RNA, History and perspective.”Ann. N.Y. Acad. Sci.vol. 660:251-262.
Xiao et al., “Adeno-associated virus (AAV) vectors for gene transfer,”Adv. Drug Del. Rev.vol. 12:201-215.
Chatterjee et al., “Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector,”Science, vol. 258:1485-1488.
Dahse et al., “Telomeres and telomerase: biological and clinical importance,”Clin. Chem.vol. 43(5):708-714.
Marshall, “Gene therapy's growing pains,”Sciencevol. 269:1050-1055.
Alam, J. et al., “Reporter genes: application to the study of mammalian gene transcription,”Anal. Biochem 188(2) (1990) , pp. 245-254.
Autexier, C. et al., “Functional reconstitution of wild-type and mutant Tetrahymena telomerase,”Genes Dev. 8(1994) , pp. 563-575.
Blasco, M. et al., “Functional characterization and developmental regulatoin of mouse telomerase RNA,”Science 269(1995) , pp. 1267-1270.
Flanagan, W. et al., “Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide,”Nature Biotechnol. 17(1) (1999) , pp. 48-52.
Greider, C. et al., “Telomeres, telomerase and cancer,”Sci. Am. 274(2) (1996) , pp. 92-97.
Harley, C. et al., “Human telomerase inhibition and cancer,”Proc. of the Annual Meeting of the Amer. Assoc. for Cancer Res., Toronto, Canada, Mar. 18-22, 1995 Abstract (1995) , pp. 671-672.
Harley, C., “Telomeres and Aging: Fact, Fancy, and the Future,”J. NIH Res. 7(1995) , pp. 64-68.
Harley, C. et al., “Telomeres and telomerase in aging and cancer,”Curr. Op. Genet. Dev. 5(1995) , pp. 249-255.
Li, X. et al., “The water channel gene in human uterus,”Biochem. Mol. Biol. Int. 32(2) (1994) , pp. 371-377.
Mehle, C. et al., “Telomere shortening in renal cell carcinoma,”Cancer Res. 54(1) (1994) , pp. 236-241.
Paau, A.,Iowa State University Letter re Novel Gene Therapy for Cancers Abstract(Feb. 24, 1995) , 2 pages.
Palmiter, R. et al., “Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene,”Cell 50(3) (1987) , pp. 435-443.
Villeponteau, B. et al., “The RNA components of human and mouse telomerases,”Sem. Cell Dev. Biol. 7(1996) , pp. 15-21.
Wahlfors, J., “EMBL Database entry,”HSSATALU, 44 Sequence database entry(Mar. 17, 1993) , 3 pages.
Zhao, J. et al., “Cloning and characterization of human and mouse telomerase RNA gene promoter sequences,”Oncogene 16(10) (1998) , pp. 1345-1350.

Affiliated with

Also associated with

Rating

Mammalian telomerase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mammalian telomerase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mammalian telomerase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4201270